The Big Picture

Psychedelic-assisted therapy is at a turning point. After decades of prohibition, a wave of clinical research has reignited interest in substances like psilocybin, MDMA, and LSD as treatments for depression, PTSD, addiction, and other mental health conditions. The question is no longer whether these therapies work — the evidence base is growing rapidly — but how they will move from clinical trials into real-world healthcare systems.

This is the central challenge of implementation. Getting a drug approved is only one step in a much longer journey. Therapies must be manufactured at scale, priced sustainably, evaluated by health technology assessment bodies, reimbursed by insurers, delivered by trained therapists, and accepted by patients, clinicians, and policymakers. Each of these steps involves its own set of stakeholders, incentives, and potential failure points.

The landscape looks very different depending on where you are. In the United States, the FDA's breakthrough therapy designation has accelerated the development of MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression. In Europe, the picture is more fragmented — the EMA operates at a continental level, but reimbursement decisions are made country by country, creating a patchwork of access.

In this section, we provide a high-level overview of where things stand today. We map the key players — from biotech companies and academic research groups to regulatory agencies and patient advocacy organizations — and outline the critical milestones ahead. Whether you're a researcher, clinician, policymaker, investor, or simply someone following this space, this is the starting point for understanding the road from research to patient access.

Our analysis draws on the Blossom research database of over 3,500 studies, regulatory filings, health technology assessments, and interviews with stakeholders across the field. We focus primarily on Europe and the United States, while also tracking developments in other jurisdictions that may offer lessons for broader implementation.